Drug assessment: responsibilities of the department

The main responsibility of the department is to assess the benefits and harms of drugs approved in Germany. For this purpose, it compares drugs with each other as well as with non-drug interventions. The aim of these comparisons is to establish which treatment alternative shows which advantages and disadvantages for patients.

In collaboration with external experts, the department prepares

  • early benefit assessments (dossier assessments)
    Dossiers submitted by the drug manufacturer to the form the basis of early benefit assessments. The results are published in the form of a dossier assessment. These early assessments are the consequence of the regulations set out in the Act on the Reform of the Market for Medicinal Products (AMNOG), which became effective in 2011.
  • benefit assessments (reports, rapid reports)
    These benefit assessments are based on our own systematic search for published and unpublished studies. These results are published as a report or rapid report.

In these assessments the department applies methods and processes adapted to the respective objectives of a project.

Further responsibilities:

  • further development of methods for assessing the benefits and harms of drugs.
  • cooperation in international working groups (especially within the European Network EUNetHTA).
  • in talks and publications, dissemination of IQWiG's methods and results as well as of other new scientific findings arising from the department's work.

Drug Assessment: Staff

Dr. med. Thomas Kaiser

Dr. med. Thomas Kaiser

Professional profile

1990: Degree in System Development. 1999: Degree in Medicine. 2002: Co-founder of the German Institute for Evidence-based Medicine (DIeM) in Cologne. 2002-2004: Appointed expert in working groups for Disease Management Programmes in the Coordination Committee and Federal Joint Committee. 2005: Doctorate in Medicine (Dr. med.). 2008: Recipient of the Bill Silverman Prize of the (together with 3 other IQWiG staff members). 2011: Recipient of the David Sackett Prize of the German Network for Evidence-based Medicine (DNEbM). 2011 (prize awarded to IQWiG's Drug Assessment Department). Since 2004: Head of IQWiG's Drug Assessment Department.

Dr. rer. nat. Beate Wieseler

Dr. rer. nat. Beate Wieseler

Professional profile

Degree in Biology (Universities of Bonn and Freiburg). 1989 - 1994: Research Associate at the Universities of Bonn, Freiburg, and Munich (LMU). 1993 - 1995: Scientific journalist. 1996 - 2005: Clinical research at "gmi” (Organization for Applied Mathematics and Informatics) and Kendle International Inc.: planning, analysis, and reporting of clinical trials. Preparation of submission dossiers. Development and conduct of workshops on topics related to clinical research and drug development. 1997 - 2005 Head of the European Medical Writing Department, Kendle International Inc. April 2005 - September 2011: Deputy Head of IQWiG's Drug Assessment Department; Since October 2011: Head of IQWiG's Drug Assessment Department.

Dr. rer. nat. Daniela Preukschat

Dr. rer. nat. Daniela Preukschat

Professional profile

Studied biology and sports science in Cologne; 2008 - 2013 Research Associate at the University of Cologne, Institute of Genetics; 2014-2016: Scientific Advisor at the Medical Advisory Service of the German Social Health Insurance (MDS), Evidence-Based Medicine Division, Essen: Preparation and Assessment of HTA Reports, Advisor to the National Association of Statutory Health Insurance Funds (); since July 2016, Research Associate in the IQWiG Drug Assessment Department; since May 2021, Head of the Chronic Diseases Division.

Katrin Nink

Katrin Nink

Professional profile

Degree in pharmacy in Bonn; postgraduate studies in health sciences in Bielefeld (MPH); 1998 - 2001: researcher at the consumer centre North Rhine-Westfalia (NRW) in health consumer protection, 2001 to 2012: Scientific Institute of the AOK (WIdO), last position: Head of the research area "Drug Index of the Statutory Health Insurance (GKV)"; since 2012: researcher at IQWiG in the Drug Assessment Department; since February 2020: Head of "Haemato-Oncology and Infectious Diseases" Devision

Volker Vervölgyi

Volker Vervölgyi

Professional profile

Studied Veterinary Medicine at the Justus Liebig University Giessen; 2003-2006 Institute of Physiology II at the Rheinische Friedrich-Wilhelms University Bonn; Doctorate (Dr. med. vet.); 2005-2009 Studies in Epidemiology at the Johannes Gutenberg University Mainz; 2006-2014 Research Associate in IQWiG's Drug Assessment Department; 2014-2019 Deputy Head of Department; since 2019 Head of the Oncology Division (solid tumours).

Dr. Sascha Abbas
Dr. Selver Altin
Anna-Katharina Barnert
Erika Baumbach
Dr. Philip Böhler
Concetta Cannistraci
Dr. Annette Christoph
Tobias Depke
Dr. Ivona Djuric
Susanne Ebrahim, Dipl.-Psych.
Gertrud Egger
Sema Erden
Christina Frings, MSc (Drug Research)
Dr. Jana Göbel
Dr. Raphaela Gorris
Dr. rer. nat. Susanne Haag
Helmut Hörn
Dr. Anne Hüning
Dr. Deborah Ingenhag-Reister
Dr. Kirsten Janke
Dr. Simone Johner
Dr. rer. nat. Lisa Junge
Jana Kalz
Michaela Florina Kerekes
Michael Köhler
Petra Kohlepp
Dr. Philip Kranz
Dr. Anke Kummer
Teresa Labahn
Yvonne Lammering
Dr. Ana Liberman
Annette Loh
Kai Lucaßen
Dr. Sebastian Meller
Dr. Ulrike Mikulić
Prateek Mishra
Dr. Bent Müller
Katrin Nink
Sabine Ostlender
Isabelle Paulußen
Anne-Kathrin Petri
Dr. rer. nat. Regine Potthast
Dr. Daniela Preukschat
Dr. Annette Pusch-Klein
Katharina Quitmann
Dr. Marc Schulte
Ulrike Seay
Dr. Virginia Seiffart
Dr. Claudia Selbach
Christian Siebel
Fabian Steinberg
Dr. Can Ünal
Elke Vervölgyi, Dipl.-Math.
Dr. med. vet. Volker Vervölgyi, MSc (Epidemiology)
Dr. Katharina Wölke
Dr. Marina Woeste
Wibeke Wothge